Here’s Why Developing Countries Can Make mRNA Covid Vaccines

THE NEW YORK TIMES, OCT 22, 2021

Workers inspecting and packing vials of the Oxford-AstraZeneca Covishield vaccine at a Serum Institute of India site in Pune, India. Video: Karan Deep Singh/The New York Times

Employees entering the Serum Institute of India campus in Pune. Video: Karan Deep Singh/The New York Times

Gennova’s manufacturing site in Pune, India. Video: Karan Deep Singh/The New York Times

Researcher Debasmita Panda at one of Gennova’s mRNA labs in Pune. Video: Karan Deep Singh/The New York Times

Workers overseeing a production line during a trial run at Gennova's vaccine manufacturing facility in Pune, India, on September 21, 2021. Photo: Karan Deep Singh/The New York Times

Workers overseeing a production line during a trial run at Gennova's vaccine manufacturing facility in Pune, India, on September 21, 2021. Photo: Karan Deep Singh/The New York Times

Workers packing pre-filled erythropoietin injections at Gennova's manufacturing facility in Pune, India. Photo: Karan Deep Singh/The New York Times

Workers packing pre-filled erythropoietin injections at Gennova's manufacturing facility in Pune, India. Photo: Karan Deep Singh/The New York Times

Dr. Sanjay Singh, the chief executive of Gennova outside his labs in the western Indian city of Pune on September 21, 2021. Photo: Karan Deep Singh/The New York Times

Dr. Sanjay Singh, the chief executive of Gennova outside his labs in the western Indian city of Pune on September 21, 2021. Photo: Karan Deep Singh/The New York Times

 

Published on Page 1, A12 and A12, Oct 23, 2021, New York edition of The New York Times